Molecular Subtypes Are Associated With Clinical Benefit in Cisplatin-Treated Metastatic Urothelial Cancer Patients
This study identifies different CHT responses by LundTax molecular subtypes in patients with mUC, where the Mes-like subtype was associated with lower response rate and shorter survival.
Authors
- Carina Bernardo (ORCID: https://orcid.org/0000-0002-1667-6510)
- Johan Abrahamsson (ORCID: https://orcid.org/0000-0003-4854-1896)
- Fredrik Liedberg (ORCID: https://orcid.org/0000-0001-8193-0370)
- Mattias Höglund (ORCID: https://orcid.org/0000-0001-9283-4421)
- Karin Holmsten (ORCID: https://orcid.org/0000-0002-3480-2322)
- Gottfrid Sjödahl (ORCID: https://orcid.org/0000-0002-7869-0473)
- Anders Ullén (ORCID: https://orcid.org/0000-0002-9023-3259)
- Pontus Eriksson (ORCID: https://orcid.org/0000-0003-3317-865X)
Institutions
- Karolinska University Hospital (SE)
- Lund University (SE)
- Karolinska Institutet (SE)
- Saint Göran Hospital (SE)
- Skåne University Hospital (SE)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1200/po.24.00209
- Citations
- 3
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.72
Funders
- Bristol-Myers Squibb
- Pfizer
- Merck KGaA
- Skåne County Council's Research and Development Foundation
- Cancerfonden
- Fondation pour la Recherche Médicale
- Stockholms Läns Landsting
- Vetenskapsrådet
- Astellas Pharma
- Cilag